Publications by authors named "Mike Burbridge"

Claim this Profile
C
CAR-T cells derived from multiple myeloma patients at diagnosis have improved cytotoxic functions compared to those produced at relapse or following daratumumab treatment.
Audrey Abecassis, Nathalie Roders, Maxime Fayon, Caroline Choisy, Elisabeth Nelson, Mike Burbridge

EJHaem· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-man, first-in-class phase I study with the monopolar spindle 1 kinase inhibitor S81694 administered intravenously in adult patients with advanced, metastatic solid tumours.
Patrick Schöffski, Ahmad Awada, Anne-Marie de la Bigne, Zakia Felloussi, Mike Burbridge

Eur J Cancer· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting DYRK1A/B kinases to modulate p21-cyclin D1-p27 signalling and induce anti-tumour activity in a model of human glioblastoma.
Andrew J Massey, Karen Benwell, Mike Burbridge, Andras Kotschy, David Lee Walmsley

J Cell Mol Med· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modeling restoration of gefitinib efficacy by co-administration of MET inhibitors in an EGFR inhibitor-resistant NSCLC xenograft model: A tumor-in-host DEB-based approach.
Elena M Tosca, Glenn Gauderat, Sylvain Fouliard, Mike Burbridge, Marylore Chenel

CPT Pharmacometrics Syst Pharmacol· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fragment-Derived Selective Inhibitors of Dual-Specificity Kinases DYRK1A and DYRK1B.
David Lee Walmsley, James B Murray, Pawel Dokurno, Andrew J Massey, Karen Benwell, Mike Burbridge

J Med Chem· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-Guided Discovery of Potent and Selective DYRK1A Inhibitors.
Csaba Weber, Melinda Sipos, Attila Paczal, Balazs Balint, Vilibald Kun, Mike Burbridge

J Med Chem· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy.
Jordi Bertran-Alamillo, Valérie Cattan, Marie Schoumacher, Jordi Codony-Servat, Ana Giménez-Capitán, Mike Burbridge

Nat Commun· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The MET/AXL/FGFR Inhibitor S49076 Impairs Aurora B Activity and Improves the Antitumor Efficacy of Radiotherapy.
Céline Clémenson, Cyrus Chargari, Winchygn Liu, Michele Mondini, Charles Ferté, Mike F Burbridge

Mol Cancer Ther· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-Based Design and Synthesis of Harmine Derivatives with Different Selectivity Profiles in Kinase versus Monoamine Oxidase Inhibition.
Balázs Bálint, Csaba Wéber, Francisco Cruzalegui, Mike Burbridge, Andras Kotschy

ChemMedChem· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Key Roles of AXL and MER Receptor Tyrosine Kinases in Resistance to Multiple Anticancer Therapies.
Marie Schoumacher, Mike Burbridge

Curr Oncol Rep· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In Vitro and In Vivo Activity of Lucitanib in FGFR1/2 Amplified or Mutated Cancer Models.
Federica Guffanti, Rosaria Chilà, Ezia Bello, Massimo Zucchetti, Monique Zangarini, Mike F Burbridge

Neoplasia· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab.
Mike F Burbridge, Céline J Bossard, Carine Saunier, Imre Fejes, Alain Bruno

Mol Cancer Ther· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Only a subset of Met-activated pathways are required to sustain oncogene addiction.
Andrea Bertotti, Mike F Burbridge, Stefania Gastaldi, Francesco Galimi, Davide Torti

Sci Signal· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Only a subset of Met-activated pathways are required to sustain oncogene addiction.
Andrea Bertotti, Mike F Burbridge, Stefania Gastaldi, Francesco Galimi, Davide Torti

Sci Signal· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Three-dimensional in vitro anglogenesis in the rat aortic ring model.
David C West, Mike F Burbridge

Methods Mol Biol· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Decrease in survival threshold of quiescent colon carcinoma cells in the presence of a small molecule integrin antagonist.
Mike F Burbridge, Virginie Venot, Patrick J Casara, Françoise Perron-Sierra, John A Hickman

Mol Pharmacol· June 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel bicyclic oxazolone derivatives as anti-angiogenic agents.
Françoise M Perron-Sierra, Alain Pierré, Mike Burbridge, Nicolas Guilbaud

Bioorg Med Chem Lett· June 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Solid-phase synthesis of alpha-substituted 3-bisarylthio N-hydroxy propionamides as specific MMP inhibitors.
Anne-Marie Chollet, Thierry Le Diguarher, Nathalie Kucharczyk, Armelle Loynel, Marc Bertrand, Mike Burbridge

Bioorg Med Chem· March 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis